Evidence map›Paper›PMID 25421437›Full record

ReviewDepression and anxiety2015

Measuring cognitive function in MDD: emerging assessment tools.

Manuela Russo, Katie Mahon, Katherine E Burdick

Open access · bronzeAbstract readReview
In one paragraph

Review in Depression and anxiety, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Manuela RussoDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Katie Mahon
Katherine E Burdick
Icahn School of Medicine at Mount Sinai · US

Funding

1/2-Pramipexole in Bipolar Disorder:Targeting Cognition (PRAM)-BDR01MH102257 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BURDICK, KATHERINE ELIZABETH · 2014 to 2016
$1.2M
Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder with ModafinilR34MH101267 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BURDICK, KATHERINE ELIZABETH · 2013 to 2015
$763k
NIMH NIH HHS R01 MH102257NIMH NIH HHS R34 MH101267
6 · The paper itself

Abstract

Cognitive impairment is emerging as an important therapeutic target in patients with psychiatric illnesses, including major depressive disorder (MDD). The objective of this general overview is to briefly review the evidence for cognitive impairment in MDD and to summarize a representative sample of cognitive assessment tools currently available to assess cognitive function in depressed patients. Study results in MDD patients with cognitive dysfunction are somewhat inconsistent, likely due to the heterogeneity of the disorder as well as the use of diverse assessment tools. Measuring cognitive changes in this population is challenging. Cognitive symptoms are typically less severe than in patients with schizophrenia and bipolar disorder, requiring greater sensitivity than afforded by existing tools. Preliminary evidence suggests antidepressant treatments may improve cognitive functioning as a direct result of ameliorating depressive symptoms; however, any procognitive effects have not been elucidated. To evaluate antidepressant efficacy in MDD patients with cognitive dysfunction, a standardized cognitive battery for use in clinical trials is essential.

Indexed as

Neuropsychological TestsAntidepressive AgentsCognition DisordersHumansMajor Depressive DisorderAntidepressive Agentsantidepressantcognitive assessmentcognitive dysfunctionmajor depressive disorder

Identifiers

PMID25421437
PMCPMC4407945
OpenAlexW1561252397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.